Keep pulling the thread on Daniel Nadler.
Open Evidence is used by an average of 40% of doctors in the United States on a daily basis.
Open Evidence became the primary platform for clinical knowledge in the United States within approximately 18 months of its launch.
Open Evidence is used approximately 20 times more than the next most-used platform in the high-stakes clinical decision support segment for doctors.
Senior leadership at major hospital systems including UCSF, MGH, Mayo Clinic, Cleveland Clinic, New York Presbyterian, Mount Sinai, and Cedars-Sinai are avid personal users of Open Evidence.
The Open Evidence platform searches across a corpus of 35 million biomedical publications.
According to estimates in the British Medical Journal and Nature, the total volume of medical knowledge now doubles every 73 days.
IL-17 inhibitors can worsen the condition of patients with Multiple Sclerosis (MS).
An internal analysis by Open Evidence estimates that the top quartile of peer-reviewed medical literature doubles every five years.
IL-23 inhibitors are considered safe and well-tolerated for patients who also have Multiple Sclerosis (MS).
Open Evidence is one of the largest sources of referral traffic to the New England Journal of Medicine, ranking after Google.
Sequoia has described Open Evidence as "a consumer internet company masquerading as a health care company."
Open Evidence has made a strategic decision to exclusively serve physicians and not patients.